Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common form of skin cancer worldwide, arising from the basal cells in the deepest layer of the epidermis. It grows slowly and rarely spreads beyond the skin, but it can cause significant local damage if left untreated. Fair-skinned individuals living in high-UV regions, including expatriates in Southeast Asia, South Asia, and the Pacific, carry elevated risk due to prolonged sun exposure.

Medicine used to treat Basal Cell Carcinoma

Efudex

Fluorouracil

1 · 5%

Utilized to target actinic keratosis and intended to support the reduction of cancerous skin cell proliferation.

From $8.67 / tube View

How basal cell carcinoma is managed

The primary treatment is physical removal: surgical excision, Mohs micrographic surgery, or cryotherapy for small, well-defined lesions. Where surgery is not suitable, for superficial BCCs, multiple lesions, or patients who cannot undergo an operation, topical treatment is a recognised alternative. Fluorouracil (5-FU) is a chemotherapy agent applied directly to the skin that disrupts cancer-cell replication; it is used for superficial BCC and is also employed in broader skin care and oncology support contexts. Any suspicious or changing lesion on the face, scalp, ears, or neck warrants prompt assessment by a dermatologist, as early detection keeps treatment straightforward.